ALK and non-small cell lung carcinoma: PROFILE 1005 was a global, multicenter, open label, single arm phase 2 study evaluating safety and efficacy of crizotinib (250 mg oral bid every 3 weeks) in patients with advanced ALK positive NSCLC who progressed after more than one cycle of chemotherapy [69].